Nonmutated self-antigen-derived cancer vaccine peptides elicit an IgE-independent but mast cell-dependent immediate-type skin reaction without systemic anaphylaxis

Journal of Immunology

Volumn 176, Issue 2, 2006, Pages 857-863

  Yamada, Akira ^a,b   Yano, Hirohisa ^b   Takao, Yukari ^a   Ono, Takeharu ^a   Matsumoto, Tomoko ^a   Itoh, Kyogo ^a,b  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; AUTOANTIGEN; CANCER VACCINE; CYCLOPHILIN B; CYSTEINE; GLUTAMIC ACID; HISTIDINE; HLA A24 ANTIGEN; IMMUNOGLOBULIN E; ISOLEUCINE; LEUCINE; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE DERIVATIVE; PHENYLALANINE; TYROSINE; VALINE;

ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DEGRADATION; FEMALE; IMMEDIATE TYPE HYPERSENSITIVITY; IN VIVO STUDY; INFLAMMATION; MALE; MAST CELL; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; SCID MOUSE; SKIN ALLERGY; SKIN TEST; SYSTEMIC DISEASE; TUMOR IMMUNITY; VACCINATION;

EID: 30744431608     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.2.857     Document Type: Article

References (22)

1. Van Der Bruggen, P., Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E. S. Schultz, J. Chapiro, B. J. Van Den Eynde, F. Brasseur, and T. Boon. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188: 51-64.
2. Yamada, A., H. Yamana, and K. Itoh. 2002. Development of peptide-based vaccines for epithelial cancer. In Research Advances in Cancer, Vol. 2. R. M. Mohan, ed. Global Research Network, India, pp. 241-247.
3. Miyagi, Y., N. Imai, T. Sasatomi, A. Yamada, T. Mine, K. Katagiri, M. Nakagawa, A. Muto, S. Okouchi, H. Isomoto, et al. 2001. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination of SART3 peptides. Clin. Cancer Res. 7: 3950-3962.
4. Gohara, R., N. Imai, T. Rikimaru, A. Yamada, M. Ichiki, M. Kawamoto, K. Matsunaga, J. Ashihara, S. Yano, M. Tamura, et al. 2002. Phase I clinical study of cyclophilin B peptide vaccine for patients with lung cancer. J. Immunother. 25: 439-444.
5. Rammensee, H.-G., T. Fried, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228.
6. Shichijo, S., M. Nakao, Y. Imai, H. Takasu, M. Kawamoto, F. Niiya, D. Yang, Y. Toh, H. Yamana, and K. Itoh. 1998. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. Exp. Med. 187: 277-288.
7. Nakao, M., S. Shichijo, T. Imaizumi, Y. Inoue, K. Matsunaga, A. Yamada, M. Kikuchi, N. Tsuda, K. Ohta, S. Takamori, et al. 2000. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J. Immunol. 164: 2565-2574.
8. Yang, D., M. Nakao, S. Shichijo, T. Sasatomi, H. Takasu, H. Matsumoto, K. Mori, A. Hayashi, H. Yamana, K. Shirouzu, and K. Itoh. 1999. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res. 59: 4056-4063
9. Gomi, S., M. Nakao, F. Niiya, Y. Imamura, K. Kawano, S. Nishizaka, A. Hayashi, Y. Sobao, K. Oizumi, and K. Itoh. 1999. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J. Immunol. 163: 4994-5004.
10. Nishizaka, S., S. Gomi, K. Harada, K. Oizumi, K. Itoh, and S. Shichijo. 2000. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res. 60: 4830-4837.
11. Kawano, K., S. Gomi, K. Tanaka, N. Tsuda, T. Kamura, K. Itoh, and A. Yamada. 2000. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. Cancer Res. 60: 3550-3558.
12. Harashima, N., K. Tanaka, T. Sasadomi, K. Shimizu, Y. Miyagi, A. Yamada, M. Tamura, H. Yamana, K. Itoh, and S. Shichijo. 2001. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of metastatic cancer patients. Eur. J. Immunol. 31: 323-332.
13. Noguchi, M., K. Kobayashi, N. Suetsugu, K. Tomiyasu, S. Suekane, A. Yamada, K. Itoh, and S. Noda. 2003. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57: 80-92.
14. Tanaka, S., M. Harada, T. Mine, M. Noguchi, R. Gohara, K. Azuma, M. Tamura, A. Yamada, A. Morinaga, M. Nishikori, et al. 2003. Peptide vaccination for patients with melanoma and other types of cancers based on pre-existing peptide-specific cytotoxic T lymphocyte precursors in the periphery. J. Immunother. 26: 357-366.
15. Mine, T., Y. Sato, M. Noguchi, T. Sasatomi, R. Gouhara, N. Tsuda, S. Tanaka, H. Shomura, K. Katagiri, T. Rikimaru, et al. 2004. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin. Cancer Res. 10: 929-937.
16. Sato, Y., H. Shomura, Y. Maeda, T. Mine, Y. Une, Y. Akasaka, M. Kondo. S. Takahashi, T. Shinohara, K. Katagiri, et al. 2003. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci. 94: 802-808.
17. Tsuda, N., K. Mochizuki, M. Harada, A. Sukehiro, K. Kawano, A. Yamada, K. Ushijima, T. Sugiyama, T. Nishida, H. Yamaria, et al. 2004. Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J. Immunother. 27: 60-72.
18. Ohkouchi, S., A. Yamada, N. Imai, T. Mine, K. Harada, S. Shichijo, Y. Maeda, Y. Saijo, T. Nukiwa, and K. Itoh. 2002. Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. Tissue Antigens 59: 259-272.
19. Fukuda, K., Y. Takao, Y. Miyazaki, K. Itoh, and A. Yamada. 2004. Natural antibodies reactive to self peptides which had been identified as cytotoxic T-lymphocyte (CTL)-directed tumor antigens. Immunobiology 209: 245-253.
20. Datar, P., S. Srivastava, E. Coutinho, and G. Govil. 2004. Substance P: structure, function, and therapeutics. Curr. Top. Med. Chem. 4: 75-103.
21. Nathan, C. 2002. Points of control in inflammation. Nature 420: 846-852.
22. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.